Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec;28 Suppl 1(Suppl 1):S21-7.
doi: 10.1007/s10637-010-9588-y. Epub 2010 Dec 3.

Histone deacetylase inhibitors in Hodgkin lymphoma

Daniela Buglio  1 , Anas Younes
Affiliations
Review

Histone deacetylase inhibitors in Hodgkin lymphoma

Daniela Buglio et al. Invest New Drugs. 2010 Dec.

Abstract

Although Hodgkin lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging. Furthermore, because of the young age of these patients, the impact of early mortality on the number of years lost from productive life is remarkable. Patients with relapsed HL post stem cell transplantation currently have no curative therapy, and are in need for new drugs and novel treatment strategies. While no new drugs have been approved for the treatment of patients with HL in more than three decades, several new agents are demonstrating promising results in early clinical trials. This review will focus on the emerging role of histone deacetylase inhibitors in patients with relapsed HL.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Zinc-dependent HDACs
Fig. 2
Fig. 2
A schematic grouping of HDAC inhibitors and their mechanisms of action
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–692. doi: 10.1016/j.cell.2007.01.029. - DOI - PMC - PubMed
    1. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007;13:1634–1637. doi: 10.1158/1078-0432.CCR-06-2076. - DOI - PubMed
    1. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420–5432. doi: 10.1038/sj.onc.1210610. - DOI - PubMed
    1. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2(Suppl 1):S4–S11. doi: 10.1038/ncponc0354. - DOI - PubMed
    1. Marsoni S, Damia G, Camboni G. A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics. 2008;3:164–171. doi: 10.4161/epi.3.3.6253. - DOI - PubMed

Publication types

MeSH terms

Substances